Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 15/20 | 0.43 |
| ▸ | CCND1 | P24385 | 4/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CCND2 | P30279 | 1/20 | 0.37 |
| ▸ | CCND3 | P30281 | 1/20 | 0.37 |
| ▸ | LATS1 | O95835 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20255149 | 0.85 | CHRNB2 (0.44) | CDK4CCND1CDK6CDK2CDK1 | |
| SCHEMBL20037555 | 0.80 | CDK4 (0.44) | CDK4CCND1CDK6CDK2CDK1 | |
| SCHEMBL13769162 | 0.80 | CDK4 (0.44) | CDK4CCND1CDK6CDK2CDK1 | |
| SCHEMBL12145921 | 0.79 | CHRNB2 (0.58) | CDK4CCND1CHRNB2CHRNA4 | |
| SCHEMBL20249272 | 0.79 | CHRNB2 (0.34) | CDK4CCND1CDK6CDK2CHRNB2 | |
| SCHEMBL28075623 | 0.77 | MAPT (0.57) | CDK4CCND1CDK6CDK2CDK1 | |
| SCHEMBL20249245 | 0.77 | CHRNB2 (0.51) | CDK4CCND1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20249236 | 0.77 | CHRNB2 (0.62) | CHRNB2CHRNA4 | |
| SCHEMBL23561133 | 0.76 | CDK4 (0.40) | CDK4CCND1CDK6CDK2CDK1 | |
| SCHEMBL82562 | 0.76 | ADRB1 (0.56) | CDK4CCND1CDK6CDK2CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CDK4 1/4885CCND1 32/4885CDK6 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.